IMAGENEBIO: Navigating Volatility & Cancer Therapy Innovation on Nasdaq
Investors eye Ikena Oncology’s $46.6M biotech bid to innovate cancer therapy amid stock volatility and a negative P/E, weighing risk against breakthrough potential.
2 minutes to read